Trial purpose
Cancer treatment
Tumor type
Multi-Cancer
Age
18+
Clinical summary
Summary
This dose escalation study has two parts, and each part has three periods: screening (up to 28 days), treatment, and follow up. After an initial screening period, ASKG315 or ASKG315 + pembrolizumab will be administered once every 3 weeks by intravenous (IV) infusion. The Part 1 dose escalation consists of 6 planned escalation cohorts, with a starting dose of 3mg. The Part 2 dose escalation consists of 4 planned escalation cohorts. Part 2 of the study will begin enrolling after Part 1 has successfully and safely dosed all participants in the first two cohorts and followed these participants through the entire DLT period.
Conditions
This trial is treating people with advanced solid cancers
Eligibility
Inclusion
- Signed informed consent form.
- Male or female ≥ 18 years of age (at the time signed consent is obtained).
- Histologically or cytologically confirmed advanced malignant solid tumor that is refractory to or intolerant of all standard therapy or for which no standard therapy is available.
- Measurable disease, per RECIST v1.1.
- ECOG Performance Status of ≤ 2.
- Life expectancy of ≥3 months, in the opinion of the Investigator.
- Adequate organ function defined.
- Fertile patients must be willing to use effective contraceptive measures (hormonal or barrier methods or abstinence, etc.) starting with the Screening visit through 90 days + 5 drug half-lives after the last dose of study treatment.
- Negative serum pregnancy test for female patients within 7 days prior to the first dose of the study drug or documentation of lack of childbearing potential.
- Willing and able to participate in the trial and comply with all trial requirements.
Exclusion
Patients who meet any of the following criteria are not allowed to be enrolled:
- Received any other investigational drug for treatment that is not commercially available within 4 weeks prior to Cycle 1 Day 1.
- Received chemotherapy, radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy, or any other anti-tumor treatments within 4 weeks prior to Cycle 1 Day 1.
- Had major organ surgery or significant trauma within 4 weeks prior to C1D1 or planning elective surgery during the study period.
- Received systemic glucocorticoid or other immunosuppressant treatment within 14 days prior to C1D1.
- Received immunomodulatory drugs, including but not limited to thymosin and interferon, within 14 days prior to C1D1.
- Received a live attenuated vaccine within 4 weeks prior to C1D1.
- Received IL-2 or IL-15 therapy within 12 weeks prior to C1D1.
- History of hematologic stem cell transplant or solid organ transplant.
- Adverse reactions to previous antitumor therapy have not recovered to CTCAE 5.0 grade ≤ 1.
- Cerebral parenchymal metastasis or meningeal metastasis with clinical symptoms.
- Have an active infection that currently requires intravenous anti-infection therapy.
- A history of human immunodeficiency virus (HIV) infection with a CD4+ T-cell count of ≤350 cells/µL at screening. HIV positive patients must be receiving adequate treatment.
- If serological evidence of chronic hepatitis B virus infection (HBV), viral load below the limit of quantification at screening.
- If serological evidence of hepatitis C virus infection (HCV), should have completed curative antiviral treatment and have HCV viral load below the limit of quantification at screening.
- Current clinically significant interstitial lung disease.
- History of serious cardiovascular or cerebrovascular diseases.
- Active or recurrent autoimmune diseases.
- History of Grade ≥ 3 Immune-Related Adverse Events (irAE) or Grade ≥ 2 immunotherapy-associated myocarditis associated with treatment with an immune checkpoint inhibitor.
- Grade ≥ 3 bleeding .
- Symptomatic with uncontrolled ascites or pleural effusion.
- History of a grade ≥ 3 allergic reaction to protein drugs.
- Known to have alcohol or drug dependence.
Inclusion
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has not spread to other parts of the body (localised).
- Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
Exclusion
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
- You are currently being treated on a clinical trial.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
AskGene Pharma, Inc.
Scientific Title
A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASKG315 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information